Bristol Myers Squibb revealed it was buying Mirati for up to $5.8 billion on Sunday, Oct. 8. That price marked a 52% premium to a 30-day average of Mirati’s stock before a Bloomberg report of a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Mirati MRTX shares ended the last trading session 13.5% higher at $44.37. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares ...

Bristol Myers Squibb (BMS) has agreed to acquire Mirati Therapeutics for up to $5.8 billion, the companies said, in a deal that expands the buyer’s cancer portfolio with Mirati’s marketed drug Krazati ...

Once considered an undruggable target, KRAS now has two FDA-approved therapies vying for a blockbuster cancer market. Mirati Therapeutics’ Krazati, also known as adagrasib, will take on Amgen’s ...

Biotech stocks are known for rapid price movements, and on Oct. 28, Mirati Therapeutics (MRTX +0.00%) will probably boost the industry's reputation for volatility. That's because the company will ...

(Reuters) -Bristol-Myers Squibb on Sunday said it will acquire cancer drugmaker Mirati Therapeutics for up to $5.8 billion, diversifying its oncology business and adding drugs it hopes can help offset ...